probenecid has been researched along with Huntington Disease in 17 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Homovanilic acid (HVA) was determined in the lumbar CSF of 12 patients with Huntington's disease and 12 with Sydenham's chorea before and after probenecid administration." | 3.66 | Homovanilic acid in Huntington's disease and Sydenham's chorea. ( Amaral, R; Conçalves, AF; Cunha, L; Diniz, M; Oliveira, CR; Pio-Abreu, J, 1981) |
| "Acetylcholinesterase (AChE) was measured in the cerebrospinal fluid (CSF) of patients with a diagnosis of Huntington's disease, depression, schizophrenia, or mania and also in the CSF of normal subjects." | 3.66 | Cerebrospinal fluid acetylcholinesterase in neuropsychiatric disorders. ( Berger, PA; Davis, KL; Hollister, LE; Livesey, J, 1979) |
| "Probenecid treatment significantly reduced the neuronal loss and the number of neuronal intranuclear aggregates." | 1.35 | Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease. ( Klivenyi, P; Vamos, E; Vecsei, L; Voros, K; Zadori, D, 2009) |
| "Sixteen patients with Huntington's chorea were treated for periods as long as 8 months with levodopa." | 1.26 | Levodopa in Huntingtons chorea. ( Sishta, SK; Templer, DI, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (82.35) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vamos, E | 1 |
| Voros, K | 1 |
| Zadori, D | 1 |
| Vecsei, L | 2 |
| Klivenyi, P | 1 |
| Cramer, H | 2 |
| Warter, JM | 1 |
| Renaud, B | 1 |
| Cunha, L | 1 |
| Oliveira, CR | 1 |
| Diniz, M | 1 |
| Amaral, R | 1 |
| Conçalves, AF | 1 |
| Pio-Abreu, J | 1 |
| Beal, MF | 1 |
| Harris, CA | 1 |
| Miranda, AF | 1 |
| Tanguay, JJ | 1 |
| Boegman, RJ | 1 |
| Beninger, RJ | 1 |
| Jhamandas, K | 1 |
| Curzon, G | 1 |
| Sishta, SK | 1 |
| Templer, DI | 1 |
| Kartzinel, R | 1 |
| Ebert, MH | 1 |
| Chase, TN | 6 |
| Davis, KL | 1 |
| Hollister, LE | 1 |
| Livesey, J | 1 |
| Berger, PA | 2 |
| Stahl, SM | 1 |
| Thiemann, S | 1 |
| Faull, KF | 1 |
| Barchas, JD | 1 |
| Sjöström, R | 2 |
| Gordon, EK | 1 |
| Ng, LK | 2 |
| Aquilonius, SM | 1 |
1 review available for probenecid and Huntington Disease
| Article | Year |
|---|---|
Serotonergic mechanisms and extrapyramidal function in man.
Topics: 5-Hydroxytryptophan; Carbidopa; Cerebellar Diseases; Creutzfeldt-Jakob Syndrome; Down Syndrome; Extr | 1974 |
16 other studies available for probenecid and Huntington Disease
| Article | Year |
|---|---|
Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease.
Topics: Age Factors; Animals; Cell Count; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose | 2009 |
Analysis of neurotransmitter metabolites and adenosine 3',5'-monophosphate in the CSF of patients with extrapyramidal motor disorders.
Topics: Adult; Basal Ganglia Diseases; Cyclic AMP; Female; Homovanillic Acid; Humans; Huntington Disease; Hy | 1984 |
Homovanilic acid in Huntington's disease and Sydenham's chorea.
Topics: Adult; Chorea; Female; Homovanillic Acid; Humans; Huntington Disease; Male; Middle Aged; Phenylaceta | 1981 |
Huntington's disease, behavioral disturbances, and kynurenines: preclinical findings and therapeutic perspectives.
Topics: Animals; Disease Models, Animal; Humans; Huntington Disease; Kynurenine; Papio; Probenecid; Rats; Re | 1996 |
Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.
Topics: Alanine; Animals; Anticonvulsants; Corpus Striatum; Dose-Response Relationship, Drug; Drug Synergism | 1998 |
CSF homovanillic acid: an index of dopaminergic activity.
Topics: Antiparkinson Agents; Brain; Dopamine; Hepatic Encephalopathy; Homovanillic Acid; Humans; Huntington | 1975 |
Levodopa in Huntingtons chorea.
Topics: Adult; Aged; Behavior; Drug Administration Schedule; Electroencephalography; Female; Homovanillic Ac | 1976 |
Intravenous probenecid loading. Effects on plasma and cerebrospinal fluid probenecid levels and on monoamine metabolites in cerebrospinal fluid.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Female; Homovanillic Acid; Humans; Hu | 1976 |
Cerebrospinal fluid acetylcholinesterase in neuropsychiatric disorders.
Topics: Acetylcholinesterase; Adult; Affective Symptoms; Choline; Circadian Rhythm; Humans; Huntington Disea | 1979 |
Neurochemistry of dopamine in Huntington's dementia and normal aging.
Topics: Adult; Aged; Aging; Brain; Dementia; Dopamine; Homovanillic Acid; Humans; Huntington Disease; Male; | 1986 |
Steady-state levels of probenecid and their relation to acid monoamine metabolites in human cerebrospinal fluid.
Topics: Adult; Aged; Benzoates; Bipolar Disorder; Blood-Brain Barrier; Female; Humans; Huntington Disease; H | 1972 |
Norepinephrine metabolism in the central nervous system of man: studies using 3-methoxy-4-hydroxyphenylethylene glycol levels in cerebrospinal fluid.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Carbon Radioisotopes; Cerebrospinal Fluid; Child; | 1973 |
Central monoamine metabolism in man. Effect of putative dopamine receptor agonists and antagonists.
Topics: Adult; Basal Ganglia Diseases; Brain; Central Nervous System Diseases; Dopamine; Haloperidol; Homova | 1973 |
Cholinergic and dopaminergic mechanisms in Huntington's chorea.
Topics: Acetylcholine; Adult; Blood Pressure; Dopamine; Female; Heart Rate; Humans; Huntington Disease; Male | 1971 |
Adenosine 3',5'-monophosphate in cerebrospinal fluid. Effect of drugs and neurologic disease.
Topics: Adolescent; Adult; Aged; Cerebellar Diseases; Child; Cyclic AMP; Dihydroxyphenylalanine; Female; Hom | 1973 |
Serotonergic-dopaminergic interactions and extrapyramidal function.
Topics: Biogenic Amines; Brain; Dihydroxyphenylalanine; Dopamine; Extrapyramidal Tracts; Humans; Huntington | 1974 |